SteadyMed Therapeutics (NASDAQ:STDY) yesterday released quarterly earnings that missed expectations and reported growing losses, but shares stayed steady. SteadyMed is a developer of hypertension and pain treatments given with a discrete, patented drug-delivery device called the PatchPump. The company is focusing on development and approval of Treyvant, a drug to treat pulmonary arterial hypertension. SteadyMed reported losses of […]
MassDevice Earnings Roundup
Staar Surgical updates on FDA warning, misses earnings on Q2
Staar Surgical (NSDQ:STAA) offered updates on the FDA warning it received in February as it released its quarterly earnings late last month. The company received a warning in February about its plant in Monrovia, Calif., where the company is headquartered. The FDA inspected the Monrovia facility from Nov. 14 last year through Feb. 4, finding 10 […]
Aethlon plans IDE, slims losses on Q1 report
Aethlon Medical (OTC:AEMD) yesterday said it plans to file for Investigative Device Exemption status for its HemoPurifier after the company’s contract with DARPA expires, and reports slimmed losses for the company and investors. In a quarterly earnings call, CEO Jim Joyce said this would be the company’s last year on contract with DARPA, with a caveat of a […]
Insulet shrinks losses but misses expectations on Q2
Insulet (NSDQ:PODD) released its 2nd quarter earnings yesterday after the closing bell on Wall Street, reporting shrinking losses but missing earnings and revenue analyst’s estimates by a fair margin. Insulet reported losses of $15.4 million, or 27¢ per share, on sales of $75.6 million for the 3 months ended June 30. That amounts to a […]
Glaukos sees losses widen in Q2
Glaukos (NYSE:GKOS) yesterday reported widening losses during its 2nd quarter, but shares held on for the glaucoma-treatment focused company. Laguna Hills, Calif.-based Glaukos reported losses of $32.5 million, or $10.96 per share, on sales of $17.8 million for the 3 months ended June 30. That amounts to a whopping 1000% plus increase in losses on sales […]
Titan Medical Q2 release shows development ramping up
Surgical robot developer Titan Medical (CVE:TMD) released its 2nd quarter earnings yesterday and reported on a handful of new agreements and operations as it continues towards production of its Sport surgical system. Titan Medical is developing a minimally invasive robotic surgical systems featuring its Single Port Orifice Robotic Technology with 3D imaging and interactive instruments. The company […]
Ocular Therapeutix slides as Q2 beats rev, misses earnings
Ocular Therapeutix (NSDQ:OCUL) announced its 2nd quarter earnings on Monday, beating expectations on revenue but missing on earnings. Ocular Therapeutics reported losses of $9.6 million, or 45¢ per share, on sales of $459,000 for the 3 months ended June 30. That amounts to a 62% increase in losses on sales growth of 373% compared with […]
Endo reports Q2 beat on rev, earnings
Endo Health Solutions (NSDQ:ENDP) reported 2nd quarter earnings today that beat expectations for revenue and earnings per share by a fair margin while continuing its acquisition plans for Par Pharmaceuticals. Endo International reported losses of $250.5 million, or $1.35 per share, on sales of $735.2 million for the 3 months ended June 30. Adjusted to […]
Dexcom jumps on Q2 sales beat despite earnings miss
Dexcom Inc. (NSDQ:DXCM) shares jumped this week after the continuous glucose monitor maker posted sales growth of nearly 60%, handily beating the forecast on Wall Street and paring its losses by some 38%. San Diego-based Dexcom reported losses of -$3.7 million, or -5¢ per share, on sales of $93.2 million for the 3 months ended […]
ReWalk misses Q2 sales mark by a mile, shares plummet
ReWalk Robotics (NSDQ:RWLK) saw shares plummet as it reported 2nd quarter earnings that widely missed analysts marks and larger losses compared to the same quarter last year. ReWalk reported losses of $5.8 million, or 48¢ per share, on sales of $610,000 for the 3 months ended June 30. That amounts to a 23.8% bottom-line loss on […]
NxStage teases at new pipeline products, announces Q2 earnings
NxStage Medical (NSDQ:NXTM) yesterday celebrated the 10 year anniversary mark for FDA approval of its System One home hemodialysis, announced new pipeline developments and Q2 earnings that beat expectations. The pipeline announcements from Lawrence, Mass.-based were said to include a next generation hemodialysis system, peritoneal dialysis system and a new critical care system, the company said. “Over […]